EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors

Paulo S do Amaral iD, Kathryn E Beckermann, Jennifer B Gordetsky, Sam S Chang, Daniel D Joyce, Kerry Schaffer, Amy N Luckenbaugh, Morgan A Lambrecht, Elizabeth G Ryan, Daniel A Barocas, Kelvin A Moses, Brian I Rini

The Oncologist · 04.04.2025 · 30 (4)

DOI: 10.1093/oncolo/oyaf004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 04.04.2025. Verfasst von Paulo S do Amaral und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, United States. Hauptthemen laut MEDLINE: Nephrectomy, Carcinoma, Renal Cell, Immune Checkpoint Inhibitors, Kidney Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objective Cytoreductive nephrectomy following immune checkpoint blockade (ICB) in metastatic renal cell carcinoma remains controversial, with limited data on its clinical and pathological outcomes. This study evaluated the outcomes of patients undergoing deferred cytoreductive nephrectomy (dCN) after ICB-based treatment, focusing on the radiologic and pathological responses, and postoperative clinical outcomes.

Methods

We retrospectively reviewed 24 patients with metastatic or locally advanced RCC who underwent dCN after ICB at a single institution between April 2018 and May 2024. We assessed the radiological response to ICB, pathological findings (presence and extent of necrosis) in resected primary tumors, and postoperative clinical outcomes, including the rate of patients without measurable disease and those who discontinued systemic therapy.

Results

Median ICB exposure prior to surgery was 11.3 months. Radiologically, 67% of patients had partial response, 29% had stable disease, and 4% had a complete response. Pathology showed 96% of specimens with necrosis, 21% of specimens showing no residual disease (pT0), and 21% exhibiting ≥95% necrosis. Postoperatively, 50% of patients had nonmeasurable disease of first follow-up scans, and 54% discontinued systemic therapy, with 9 patients remaining on surveillance at last follow-up. Limitations include the small sample size and retrospective design.

Conclusion

Deferred CN following ICB therapy is feasible. Extensive necrosis in the resected surgical specimen after ICB-based therapy requires further investigation as a prognostic marker for durable responses off systemic therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NephrectomyCarcinoma, Renal CellImmune Checkpoint InhibitorsKidney NeoplasmsCytoreduction Surgical ProceduresHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultTreatment OutcomeNeoplasm Metastasis

Stichwörter der Autor:innen

deferred cytoreductive nephrectomyimmunotherapykidney cancernecrosistreatment de-escalation

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, United States.

ORCID-Profile: Paulo S do Amaral

Förderung

  • NCI NIH HHS

Zitieren

APA

do Amaral, P. S., Beckermann, K. E., Gordetsky, J. B., Chang, S. S., Joyce, D. D., Schaffer, K., Luckenbaugh, A. N., Lambrecht, M. A., Ryan, E. G., Barocas, D. A., Moses, K. A., & Rini, B. I. (2025). Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors. The Oncologist, 30(4). https://doi.org/10.1093/oncolo/oyaf004

Vancouver

do Amaral PS, Beckermann KE, Gordetsky JB, Chang SS, Joyce DD, Schaffer K, et al. Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors. The Oncologist. 2025;30(4). doi:10.1093/oncolo/oyaf004

BibTeX
@article{doAmaral2025,
  author = {do Amaral, Paulo S and Beckermann, Kathryn E and Gordetsky, Jennifer B and Chang, Sam S and Joyce, Daniel D and Schaffer, Kerry and Luckenbaugh, Amy N and Lambrecht, Morgan A and Ryan, Elizabeth G and Barocas, Daniel A and Moses, Kelvin A and Rini, Brian I},
  title = {Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors},
  journal = {The Oncologist},
  year = {2025},
  volume = {30},
  number = {4},
  doi = {10.1093/oncolo/oyaf004}
}
Kostenlos starten →